Search research articles
Contact Us
Filters
Showing results (431-440 of 459) with videos related to
Page
of 46
Sort By:
International Psychogeriatrics
|
August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial
Paul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
Vaccine
|
October 12, 2021
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study
Corinne Vandermeulen, Isabel Leroux-Roels, James Vandeleur, et al.
The American Journal of Psychiatry
|
January 16, 2016
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial
Lon S Schneider, Constantine Frangakis, Lea T Drye, et al.
Journal of Psychiatric Research
|
January 7, 2016
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease
Jeffery Newell, Jerome A Yesavage, Joy L Taylor, et al.
The Lancet. Infectious Diseases
|
March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
Plos Pathogens
|
October 21, 2014
The pH-responsive PacC transcription factor of Aspergillus fumigatus governs epithelial entry and tissue invasion during pulmonary aspergillosis
Margherita Bertuzzi, Markus Schrettl, Laura Alcazar-Fuoli, et al.
Journal of Psychiatric Research
|
April 27, 2016
Principal components analysis of agitation outcomes in Alzheimer's disease
Jerome A Yesavage, Joy L Taylor, Leah Friedman, et al.
The Journal of Infectious Diseases
|
July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial
Chijioke Bennett, E Joy Rivers, Wayne Woo, et al.
Science Advances
|
December 6, 2024
Metasurface spectrometers beyond resolution-sensitivity constraints
Feng Tang, Jingjun Wu, Tom Albrow-Owen, et al.
Nucleic Acids Research
|
July 9, 2018
Generating genomic platforms to study Candida albicans pathogenesis
Mélanie Legrand, Sophie Bachellier-Bassi, Keunsook K Lee, et al.
Page
of 46
Search research articles
Search
Showing results (431-440 of 459) with videos related to
Sort By:
Page
of 46
International Psychogeriatrics
|
August 26, 2015
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial
Paul B Rosenberg, Lea T Drye, Anton P Porsteinsson, et al.
Vaccine
|
October 12, 2021
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study
Corinne Vandermeulen, Isabel Leroux-Roels, James Vandeleur, et al.
The American Journal of Psychiatry
|
January 16, 2016
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial
Lon S Schneider, Constantine Frangakis, Lea T Drye, et al.
Journal of Psychiatric Research
|
January 7, 2016
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease
Jeffery Newell, Jerome A Yesavage, Joy L Taylor, et al.
The Lancet. Infectious Diseases
|
March 9, 2024
Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial
Chijioke Bennett, Wayne Woo, Mark Bloch, et al.
Plos Pathogens
|
October 21, 2014
The pH-responsive PacC transcription factor of Aspergillus fumigatus governs epithelial entry and tissue invasion during pulmonary aspergillosis
Margherita Bertuzzi, Markus Schrettl, Laura Alcazar-Fuoli, et al.
Journal of Psychiatric Research
|
April 27, 2016
Principal components analysis of agitation outcomes in Alzheimer's disease
Jerome A Yesavage, Joy L Taylor, Leah Friedman, et al.
The Journal of Infectious Diseases
|
July 25, 2024
Immunogenicity and Safety of Heterologous Omicron BA.1 and Bivalent SARS-CoV-2 Recombinant Spike Protein Booster Vaccines: A Phase 3 Randomized Clinical Trial
Chijioke Bennett, E Joy Rivers, Wayne Woo, et al.
Science Advances
|
December 6, 2024
Metasurface spectrometers beyond resolution-sensitivity constraints
Feng Tang, Jingjun Wu, Tom Albrow-Owen, et al.
Nucleic Acids Research
|
July 9, 2018
Generating genomic platforms to study Candida albicans pathogenesis
Mélanie Legrand, Sophie Bachellier-Bassi, Keunsook K Lee, et al.
Page
of 46